I. Weinstein

Molecular Biology · 2002–2008

A researcher in the Science corpus: 3 papers; trusts 3 researchers and is trusted by 24 researchers here, as inferred from the citation graph.

Subfields

Whom I. Weinstein trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Adams
  2. W. Kaelin
  3. C. Sawyers

Who trusts I. Weinstein overall

  1. Ji Luo
  2. James E. Bradner
  3. Andrew K. Joe
  4. William Pao
  5. M. Moasser
  6. N. Solimini
  7. H. Zahreddine
  8. Meital Gabay
  9. M. Dawson
  10. Stephen J. Elledge

Papers from I. Weinstein's perspective

Ordered by how strongly the researchers I. Weinstein trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (Science)
  2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
  3. Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC (Science)
  4. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. (New England Journal of Medicine)
  5. Epigenetics in human disease and prospects for epigenetic therapy (Nature)
  6. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways (Science)
  7. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. (New England Journal of Medicine)
  8. Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy (Nature Clinical Practice Oncology)
  9. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. (New England Journal of Medicine)
  10. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. (Journal of the National Cancer Institute)

Their papers